Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Regulatory News (ONC)

  • This share is currently suspended. It was suspended at a price of 1.2699
  • There is currently no data for ONC

PDMR Dealing

25 Mar 2020 12:42

RNS Number : 5784H
Oncimmune Holdings PLC
25 March 2020
Β 

Oncimmune Holdings plc

Β 

("Oncimmune" or the "Company")

Β 

PDMR Dealing

Β 

Oncimmune Holdings plc (AIM: ONC.L),Β a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening,Β detection and care of cancer, has been notified that Meinhard Schmidt, PDMR and Non-Executive Chairman, has purchased 18,000 ordinary shares of Β£0.01 each in the Company ("Ordinary Shares") for 49 pence per share on 24 March 2020.

Β 

Following this transaction, Meinhard has a total interest in the Company of 18,000 Ordinary Shares, representing approximately 0.03 per cent of the Company's issued Ordinary Share capital. Β 

Β 

This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.

Β 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

Β 

Β 

Details of the person discharging managerial responsibilities / person closely associated

Β 

a)

Β 

Name

Β 

Meinhard Schmidt

2

Β 

Reason for the notification

a)

Β 

Position/status

Β 

Non-Executive Chairman

b)

Β 

Initial notification /Amendment

Β 

Initial notification

3

Β 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Β 

a)

Β 

Name

Β 

Oncimmune Holdings plc

b)

Β 

LEI

213800HCYIWT6YPI1I02Β 

4

Β 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Β 

Description of the financial instrument, type of instrument

Ordinary Shares of Β£0.01 each

Β 

Β 

Β 

Identification code

ISIN: GB00BYQ94H38

Β 

Β 

b)

Β 

Nature of the transaction

Β 

Purchase of shares

c)

Β 

Price(s) and volume(s)

Β 

Β 

Β 

Β 

Β 

Β 

Price

Volume

Β 

Β 

Β 

Β£0.49

18,000

Β 

Β 

Β 

Β 

Β 

Β 

d)

Β 

Aggregated information

Β 

Β 

Β 

- Aggregated volume

Same as above

Β 

Β 

- Price

Β 

Β 

Β 

e)

Β 

Date of the transaction

Β 

24 March 2020

f)

Β 

Place of the transaction

London stock exchange, AIM

Β 

For further information:

Oncimmune Holdings plc

Andrew Stewart, General Counsel and Company Secretary

contact@oncimmune.com Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
DSHKKPBQBBKDDNB
Date   Source Headline
13th Feb 20187:00 amRNSInterim Results for the half year ended 30 Nov 17
5th Feb 20187:01 amRNSUniversity of Nottingham share sale
5th Feb 20187:00 amRNSHoldings in Company
2nd Feb 20184:45 pmRNSTotal Voting Rights
29th Jan 20187:00 amRNSFirst tranche of £10m equity investment
23rd Jan 20187:00 amRNSBusiness Update and Notice of Interim Results
22nd Jan 201811:21 amRNSResult of General Meeting
9th Jan 20187:00 amRNSAppointment of Non-Executive Director
4th Jan 20187:30 amRNSNotice of General Meeting
2nd Jan 20187:00 amRNSFramework agreement, licence and £10m investment
21st Dec 20177:00 amRNSValidation of EarlyCDT®-Liver test
30th Nov 20173:53 pmRNSHolding(s) in Company
29th Nov 20179:55 amRNSResult of AGM
27th Nov 20177:00 amRNSAppointment of joint brokers
24th Nov 20177:00 amRNSSatisfaction of Delayed Completion Placing
22nd Nov 20177:00 amRNSDeadline extended for Delayed Completion Placing
16th Nov 20177:00 amRNSDistribution agreement signed for Iran
9th Nov 20177:00 amRNSLaunch of "Finger Stick" Sample Collection
3rd Nov 20177:00 amRNSAnnual Report and Accounts and AGM Notification
27th Oct 201710:32 amRNSDirector/PDMR Shareholding
20th Oct 20177:00 amRNSResults for the year ended 31 May 2017
18th Oct 20177:00 amRNSDistribution Agreement in Poland
10th Oct 201711:15 amRNSHoldings in Company
10th Oct 20177:00 amRNSNotice of Results
27th Sep 20172:11 pmRNSSuccessful £5.0m placing
26th Sep 20175:12 pmRNSProposed placing to raise up to £5.3m
19th Sep 20177:00 amRNSEarlyCDT®-Lung Kit Distribution Agreements
18th Sep 20177:00 amRNSData presented at the 11th Annual ILCA
14th Sep 20177:00 amRNSBusiness Update
29th Aug 20177:00 amRNSOncimmune and Scancell Present Data
20th Jul 20171:59 pmRNSExercise of Options & 2007 Share Option Scheme
7th Jul 20177:00 amRNSHolding(s) in Company
5th Jun 20177:00 amRNSBusiness Update and New Distribution Agreements
31st May 20177:00 amRNSCE Mark for EarlyCDT-Lung Kit
17th May 20177:00 amRNSGRANT OF OPTIONS
28th Apr 20177:00 amRNSFirst Distribution Agreements Signed
24th Apr 20179:18 amRNSGRANT OF OPTIONS
3rd Apr 20177:00 amRNSAppointment of Senior VP, MA & Reimbursement
3rd Apr 20177:00 amRNSGRANT OF OPTIONS AND DEALING BY PDMR
29th Mar 20173:35 pmRNSHolding(s) in Company
10th Feb 20177:00 amRNSInterim Results
8th Feb 20177:00 amRNSNotice of Interim Results
6th Dec 20167:00 amRNSPositive interim data from NHS Screening Trial
30th Nov 20165:47 pmRNSPUBLIC DISCLOSURE OF TRANSACTIONS BY PDMR
30th Nov 201610:47 amRNSResult of Annual General Meeting
8th Nov 20166:25 pmRNSGrant of options
7th Nov 20167:00 amRNSFinal Results
24th Oct 20167:00 amRNSNotice of Full Year Results
11th Oct 20167:00 amRNSBoard Appointment
22nd Sep 20167:00 amRNSAppointment of Chief Commercial Officer Asia

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.